Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Olimmune
Los Angeles, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Before its acquisition by Scopus BioPharma, Olimmune was developing OLIM-01 and related CpG-STAT3 oligonucleotide immunotherapies for treatment‑resistant and metastatic cancers, with IND submissions for genitourinary and head and neck cancers anticipated but not yet filed and no clinical data reported.[1][2]
- Therapeutic areas
- Oncology
- Modalities
- RNA therapySynthetic oligonucleotideSmall interfering RNAAntisense oligonucleotideDecoy oligonucleotide
- Industry
- Biotech
02
Partnerships
City of Hope
Beyond the preview
Go deeper on Olimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olimmune.